Borthwick Nicola, Silva-Arrieta Sandra, Llano Anuska, Takiguchi Masafumi, Brander Christian, Hanke Tomáš
The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
IrsiCaixa AIDS Research Institute-HIVACAT, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain.
Vaccines (Basel). 2020 Jan 16;8(1):28. doi: 10.3390/vaccines8010028.
CD4 T-cell responses play an important role in the immune control of the human immunodeficiency virus type 1 (HIV-1) infection and as such should be efficiently induced by vaccination. It follows that definition of HIV-1-derived peptides recognized by CD4 T cells in association with HLA class II molecules will guide vaccine development. Here, we have characterized the fine specificity of CD4 T cells elicited in human recipients of a candidate vaccine delivering conserved regions of HIV-1 proteins designated HIVconsv. The majority of these 19 most immunogenic regions contained novel epitopes, that is, epitopes not listed in the Los Alamos National Laboratory HIV Sequence Database, which were able in vitro to stimulate vaccinees' CD4 T cells to proliferate and produce interferon-γ and tumor necrosis factor-α. Accumulation of HLA class II epitopes will eventually accelerate development of HIV-1 prophylactic and therapeutic vaccines.
CD4 T细胞反应在人类免疫缺陷病毒1型（HIV-1）感染的免疫控制中发挥着重要作用，因此应通过疫苗接种有效诱导。由此可见，确定与HLA II类分子相关的CD4 T细胞识别的HIV-1衍生肽将指导疫苗开发。在此，我们已经对在接种了一种递送HIV-1蛋白保守区域（命名为HIVconsv）的候选疫苗的人类受试者中引发的CD4 T细胞的精细特异性进行了表征。这19个最具免疫原性的区域中的大多数都包含新表位，即未列入洛斯阿拉莫斯国家实验室HIV序列数据库的表位，这些表位在体外能够刺激疫苗接种者的CD4 T细胞增殖并产生干扰素-γ和肿瘤坏死因子-α。HLA II类表位的积累最终将加速HIV-1预防性和治疗性疫苗的开发。
Zotero 插件